Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?
Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells adaptimmune.com. Adaptimmune’s proprietary platform, known as SPEAR T-cells (Specific Peptide Enhanced Affinity Receptor), allows it to design TCRs that recognize tumor-specific antigens (such as MAGE-A4 or NY-ESO-1) and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to